Navigation Links
Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
Date:9/8/2010

SAN FRANCISCO and ILLKIRCH, France, Sept. 8 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.  

JX-594, Jennerex's lead cancer biotherapeutic product, has shown anticancer activity and a well-tolerated safety profile in Phase 1 and Phase 2 clinical trials to date(1). Objective tumor response has been demonstrated in a variety of cancers including liver, colon, kidney, lung and melanoma.

Jennerex has awarded Transgene exclusive rights to develop and commercialize JX-594 in Europe, the CIS and the Middle East.  Jennerex and Transgene will co-develop JX-594 worldwide, with Transgene responsible for development costs and for clinical development in its licensed territories, pursuant to the JX-594 global development plan. Transgene is responsible for commercialization and has the right to manufacture JX-594 in the Transgene territory. As part of this agreement Transgene has made an upfront equity investment in Jennerex. Jennerex is further eligible to earn a total of up to $116 million in development and registration milestones as well as double digit royalties on a tiered structure. In addition, Jennerex has an option for co-promotion and profit-sharing in the five major European countries.

The development plan will focus initially on Hepatocellular Carcinoma (HCC), both in first line and in second line, and on colorectal cancer. Transgene and Jennerex intend to initiate a large randomized controlled phase 2b/3 clinical program in HCC patients. 
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
2. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
3. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
4. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
7. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
8. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
9. Sigma® Life Science Enters Genetically Modified Cell Market
10. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
11. Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... LONDON , May 6, 2015 /PRNewswire/ ... clean fuel membrane specialist, announced today that it has ... based Pacific Ethanol, Inc. (Nasdaq: PEIX ) for the ... is to reduce the consumption of water, ... ethanol while  increasing product output. This project ...
(Date:5/6/2015)... , May 6, 2015 Dr Jaspreet ... Massey University, will deliver a speech at the 2015 Asian ... the Shanghai New Expo Center.  ... introduce to attendees the topic: ,Potato Starch: A Potential ... Smart Foods., Co-editor of a 528 page ...
(Date:5/5/2015)... RURO, Inc., a leading LIMS, RFID and ... latest major content upgrade to its bestselling, Commercial Off-The-Shelf ... is a significant advancement of FreezerPro® system , ... while also simplifying , New FreezerPro® ... Download available immediately for free to “Gold” support ...
(Date:5/5/2015)... 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... for the three months ended March 31, 2015 and ... are in Canadian dollars. Effective July ... from May 31 to December 31. As a result ... is for the three months ended March 31, 2015, ...
Breaking Biology Technology:Whitefox Signs Agreement With Pacific Ethanol Inc. 2Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2RURO Releases version 7 of FreezerPro® software 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8
... N.J., Jan. 21 Wedgewood Pharmacy has,announced ... (Bevacizumab) to,retinal specialists and ophthalmologists who request ... Avastin,s manufacturer, Genentech,s, decision,( http://www.lucentis.com/lucentis/pdf/announcement.pdf ) to ... of January 1., Avastin is commonly ...
... 21 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... of portions of the recently completed and ... planning for 2008,and employee recognition ceremonies., ... Mr. Zhang, Director and General Manager of ...
... chocolate present risk, OAKLAND, Calif., Jan. 21 ... whether from coffee, tea, caffeinated soda or hot,chocolate ... a new study,by the Kaiser Permanente Division of ... symptoms of nausea, vomiting and caffeine,aversion that tended ...
Cached Biology Technology:Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 2Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 3Kiwa Posts Video of 2007 Annual Management Meetings 2Kiwa Posts Video of 2007 Annual Management Meetings 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 4
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... bubbling vat of chemical reactants, and complex biochemical circuitry ... Many scenarios can play out depending on a fixed ... precisely predicted chemicals combining, genes triggering cascades of ... Predicting possible outcomes from a set of rules that ...
... A research team from the School of Basic ... that Radix Achyranthis Bidentatae can inhibit advanced glycation ... frontal cortex, and improve learning and memory capabilities ... effect on advanced glycation end product accumulation is ...
... up city parks, or scale back their driving to curb ... and ride free on the efforts of others. They watch ... Or they run their lawn sprinklers during a drought while ... A new report in Psychological Science in the Public ...
Cached Biology News:Computer can infer rules of the forest 2Trust in leaders, sense of belonging stir people to safeguard common goods, analysis shows 2Trust in leaders, sense of belonging stir people to safeguard common goods, analysis shows 3
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... a software package that provides crystallographers ... custom buffer creation, set-up of experimental ... trials. The software helps crystallographers through ... protein crystallography: Design ...
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
... 96-well semi-skirted PCR plate, Directly compatible ... sequencers, Flat deck for improved sealing characteristics ... adhesive seals, mats or cap strips, Certified ... DNA We are part of Thermo Fisher ...
Biology Products: